Navigation Links
Nephrologists Indicate High Interest in AMAG Pharmaceuticals' Newly Approved Feraheme According to Latest BioTrends Report
Date:8/4/2009

EXTON, Pa., Aug. 4 /PRNewswire/ -- BioTrends Research Group, Inc. released TreatmentTrends(R): US Nephrology, a syndicated report analyzing treatment practices, attitudes and perceptions based on online survey results from over 200 US Nephrologists. The survey was fielded in late May and focuses on trends in treatment patterns for renal anemia, secondary hyperparathyroidism and hyperphosphatemia.

Nephrologists are extremely interested in AMAG's new IV iron product, Feraheme, which was approved by the FDA on June 30, 2009. Nephrologists identified two areas in particular where both American Regent / Fresenius' Venofer and Watson's Ferrlecit seem to fall short, where AMAG may have an advantage. According to Nephrologists, the current products underperform in the CKD-ND setting on quick administration and minimal staff time. These administration attributes are areas where Nephrologists perceive Feraheme to have a competitive advantage. The uptake of Feraheme and its impact on the anemia market will be further explored in LaunchTrends(TM): Feraheme, a three-wave report series from BioTrends tracking trial, adoption and usage at one month, three months, and six months post launch.

The longer term changes in the anemia market are overshadowed by the pending dialysis bundled payment system scheduled to be implemented in 2011. According to a recent report published by BioTrends on anticipated impact of the dialysis bundle, Medical Directors foresee the increased use of IV iron to spare the use of ESAs (such as Amgen's Epogen) as well as IV iron brand selection being heavily influenced by price. Although the bundled payment only impacts the dialysis market, reimbursement has a high degree of influence on brand choice in the chronic kidney disease non dialysis (CKD-ND) market as well. This adds importance to Nephrologists' perception that Centocor-Ortho Biotech's Procrit has a competitive advantage over Amgen's Aranesp on "minimal hassles with prior authorizations" and "adequate reimbursement".

In the phosphate binder market, Genzyme's sevelamer compounds are being used to treat almost half of the dialysis patients. At one year post launch, virtually all Nephrologists have started to use Renvela, the new formulation. FMC's PhosLo is under mounting pressure from generic versions of the product and Nephrologists are showing little resistance - 80% either allow substitution or prescribe the generic version outright. Shire's Fosrenol is the only brand for which Nephrologists project significant increases in market share. Despite significantly higher performance ratings on the most important attribute (Efficacy), Fosrenol is still typically reserved for second or third line therapy or as an additive product for patients not well controlled on their current regimen. According to the survey, the need for new phosphate binders and PTH modifiers is relatively high compared to the need for new ESA and IV iron therapies. Particularly in the phosphate binder market, there are a number of important product attributes where current products fall short, making room for potential new product entrants.

In the PTH modifier market, the Vitamin D products continue to try to differentiate. While Abbott's Zemplar performs significantly better than Genzyme's Hectorol on almost every product attribute, Nephrologists perceive room for improvement for both products in a number of areas including hypercalcemia, hyperphosphatemia, and impact on calcification. Although these are areas where Amgen's Sensipar has a competitive advantage, Sensipar's reimbursement and tolerability profile, as well as the fact that Nephrologists continue to reserve it for patients with extremely elevated PTH, seems to hold it back from being used in more than one-third of hemodialysis patients. In the oral Vitamin D market, Q209 marked the first quarter where Abbott's Zemplar capsules saw a year over year decrease in market share. Hectorol PO also declined year over year, but together these newer analogues still account for roughly half of the CKD patient share while calcitriol remains the market share leader.

The next wave of TreatmentTrends(R): US Nephrology will field in late August in tandem with surveys directed at two ancillary renal care audiences, Anemia Managers and Renal Dietitians.

About BioTrends Research Group, Inc.

BioTrends Research Group, Inc. (www.bio-trends.com) provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact us at (610) 363-3872 or www.bio-trends.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.


'/>"/>
SOURCE BioTrends Research Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. New Study by BioTrends Highlights Practice Management Shifts Among Canadian Nephrologists
2. Study identifies reasons patients referred late to nephrologists
3. Nephrologists summarize new renal research during public policy news briefing at Renal Week
4. Studies Indicate Good Nutrition Linked to Eye Health
5. BioGlue(R) Surgical Adhesive Hits 500,000 Procedure Milestone Worldwide, Company Data Indicates
6. Clinical Study Data Indicates that Celliant Reduces Pain
7. Study supports validity of test that indicates widespread unconscious bias
8. New study indicates radiologists need standards to ensure optimal visual accuracy
9. New study indicates that parents influence on childrens eating habits is small
10. Milliman Indicates 2009 Medical Cost for American family of four Exceeds $16,700 Based on 7.4% Cost Increase
11. New Study Indicates Changes in Cigarette Design Have Increased Lung Cancer Risk and Tobacco Regulation Can Greatly Reduce Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... ... have been diagnosed with endometriosis. These women need a treatment plan to not ... comprehensive approach that can help for preservation of fertility and ultimately achieving a ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... First ... United States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell ... facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive ...
(Date:6/24/2016)... , ... June 24, 2016 , ... A recent ... most people are unfamiliar with. The article goes on to state that individuals are ... many of these less common operations such as calf and cheek reduction. The Los ...
(Date:6/24/2016)... ... ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys are ... for this recognition are considered among the top 2 percent of lawyers practicing within ... of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. Bloom, ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The ... published in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... N.C. , June 24, 2016  Consumers ... decisions and regulators/payers have placed more emphasis on ... environment, patient support programs in the pharmaceutical industry ... patients, medications. Consequently, pharmaceutical companies are focusing on ... they are providing products and services that improve ...
(Date:6/24/2016)... , June 24, 2016   Bay ... Rehabilitation Network,s Dean Center for Tick Borne ... Medicine and Rehabilitation, MIT Hacking Medicine, University of ... Innovation, today announced the five finalists of ... Lyme disease.  More than 100 scientists, clinicians, researchers, ...
(Date:6/24/2016)... Va. , June 24, 2016 The ... set of recommendations that would allow biopharmaceutical ... (HCEI) with entities that make formulary and coverage decisions, ... the "value" of new medicines. The recommendations ... does not appear on the drug label, a prohibition ...
Breaking Medicine Technology: